�鶹��

A Danish research team led by Francesco Sergi-Lindell (Rigshospitalet) aims to develop an innovative treatment for patients with advanced and incurable prostate cancer. Securing a “Frontier Grant” of 5 million DKK marks a significant stride forward in their endeavours to help this patient group, who currently faces limited treatment options.
 

Prostate cancer stands as the second-leading cause of cancer-related deaths among Danish men, resulting in approximately 1,200 fatalities annually. While many types of prostate cancer respond to treatments targeting the male sex hormone testosterone, a subset of patients develops an advanced stage known as metastatic castration-resistant prostate cancer (mCRPC) and have only a few treatment options, if any. At this stage, the cancer has spread to other parts of the body and no longer responds to traditional hormone therapies.

Radioligand therapy aims to help patients with incurable prostate cancer

New radioligand therapy aims to help patients with incurable prostate cancer